Welcome to our dedicated page for Tracon Pharmaceu news (Ticker: TCON), a resource for investors and traders seeking the latest updates and insights on Tracon Pharmaceu stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tracon Pharmaceu's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tracon Pharmaceu's position in the market.
TRACON Pharmaceuticals (NASDAQ:TCON) reported its financial results for Q1 2020, showing a net loss of $4.0 million, down from $7.2 million in Q1 2019. Cash and cash equivalents stood at $14.1 million, expected to fund operations into Q1 2021. The company completed a Type B meeting with the FDA, agreeing on the ENVASARC trial design for envafolimab targeting soft tissue sarcomas. TRACON anticipates dosages to start in H2 2020 and aims for commercialization in 2023. The company also amended its agreement with Aspire Capital for $15 million in stock purchases and retained rights to TRC253.
TRACON Pharmaceuticals (NASDAQ:TCON) announced a successful Type B pre-IND meeting with the FDA regarding the pivotal ENVASARC trial for envafolimab, aimed at treating certain sarcoma subtypes. The trial, expected to begin in late 2020, will enroll 160 patients across two cohorts. The primary endpoint is the objective response rate (ORR). Envafolimab is a subcutaneous PD-L1 antibody, currently in Phase 1 trials in the U.S. and Japan, with potential registration in China based on ongoing studies.
TRACON Pharmaceuticals (NASDAQ:TCON) announced it will report its first quarter 2020 financial and operational results on May 13, 2020, post market close. The company will also host a conference call at 4:30 pm ET for discussions on corporate activities and results. TRACON is focused on developing targeted therapies for cancer and has a pipeline that includes multiple drug candidates, including Envafolimab for sarcoma and TRC102 for lung cancer. The company seeks partnerships to manage regulatory and clinical development and shares costs and risks.